Adverse Event reporting information can be found in footer

TWICE DAILY PENTASA® DOSING IS EFFICACIOUS IN PAEDIATRICS1

Request a Meeting

TWICE DAILY PENTASA® DOSING IS EFFICACIOUS IN PAEDIATRICS1

Artboard-23AnneShopSidebar-1

PENTASA formulations are licensed for achieving and maintaining remission in children from the age of 6 and upwards:2-5

Paediatric Formulations

Results from a multi-centre, investigator-initiated, randomised controlled, investigator-blinded induction of remission trial1

Primary endpoint was mean PUCAI score between the two arms (OD and BD dosing) at week 6. At week 6, there was no difference in the median PUCAI score between the OD and BD groups (p=0.48).*

COMPLETE REMISSION:

parkAsset-1@4x-1

PUCAI<10 points and a change of at least 10 points from baseline

RESPONSE:

parkAsset-1@4x-1

PUCAI≥10 points (active disease) but an improvement of at least 20 points

*PENTASA® is licensed to be taken in divided doses only in paediatrics. †Weight-based dosing based on 75mg/kg/day.
PUCAI = Paediatric UC disease activity index, UC = Ulcerative colitis.
Note: PENTASA® OD is not licensed for paediatric use in the UK.

1g PENTASA® sachet† BD for 6 weeks

Study Summary

6 week study, 83 patients (ITT), dosing based on weight (75mg/kg/day) rounded to multiples of 500mg (with a max dose of  3g daily)

 

Patient Numbers Dose amount Dose frequency Rectal dose
40 15-<20kg 1,000 mg (500 mg, 500 mg) Twice-daily
20-<30kg 1,500 mg (1,000 mg, 500 mg)
30-<40kg 2,000 mg (1,000 mg, 1,000 mg)
≥40kg 3,000 mg (1,500 mg, 1,500 mg)

ITT = Intention to treat.

Key Inclusion Criteria

  • Children 4-18 years of age* with body weight ≥15kg
  • Confirmed diagnosis of UC in mild to moderate disease activity according to PUCAI (score of 10-55 points)

Key Exclusion Criteria

  • Proctitis only, IBD (Inflammatory Bowel Disease) unclassified, current systemic infection, presence of stool pathogens at screening (culture, parasites and Clostridium difficile) and significant concurrent illness (e.g. renal and hepatic failure or pancreatitis)

Safety results:

  • 23% of patients (n=9/40) in the BD group had an adverse event
  • The most common adverse events in the BD group were: Disease exacerbation (3 total), Headache (2 total), Fever (2 total), Nausea (2 total)
  • None of the SAEs were thought to be related to the study drug

*PENTASA® (500 mg tablets, 1g, 2g and 4g sachets) is licensed for children from the age of 6 and older, and given in divided doses.
SAEs = Serious adverse events

PENTASA formulations are licensed for achieving and maintaining remission in children from the age of 6 and upwards:

  • Turner D, et al. J Crohn’s Colitis. 2017;11:527–533.
  • Pentasa Slow Release Tablets 500 mg. SmPC.
  • Pentasa Sachet 1 g. SmPC.
  • Pentasa Sachet 2 g. SmPC.
  • Pentasa Sachet 4 g. SmPC.
Compliance in Paediatrics
Paediatric Formulations
Pentasa in Adults
Resources

Job Code: UK-PA-2000023 - Date of preparation: October 2020

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.